Solventum (SOLV) Stifel 2025 Healthcare Conference summary

Transformation progress and strategic initiatives

• Achieved strong sales, margin, and EPS performance, with nearly every segment beating consensus projections.

• Transformation is ahead of plan in all three phases: sales growth, margin expansion, and portfolio management.

• Increased sales growth guidance to the high end of 2.5%-3.5%, nearly tripling previous growth rates.

• Launched a new restructuring program to support margin expansion through 2026, addressing tariff and TSA headwinds.

• Divested the purification filtration business, strengthening the balance sheet and enabling offensive portfolio optimization.

Portfolio optimization and SKU rationalization

• Removed 8% of SKUs globally, streamlining supply chain and reducing rebranding costs.

• SKU rationalization focused on eliminating low-profit and non-strategic products, with significant downstream benefits for supply and demand planning.

• No further major SKU reduction waves planned; ongoing fine-tuning will continue.

Division and innovation focus

• Infection Prevention and Surgical Solutions (IPSS) division created specialized sales and marketing teams, improving focus and execution.

• Transformation from applied materials science to a medical device company, with cross-functional leadership and portfolio optimization.

• Innovation engine restructured, with new R&D teams and governance; three new products launched in sterilization assurance in the last two quarters.

• Advanced wound care and dental segments also launched new products, driving growth.